Tanzania Oncology Therapeutics Market Report 2022 to 2030

Tanzania Oncology Therapeutics Market Analysis

$ 3999

By 2030, it is anticipated that the Tanzania Oncology Therapeutics Market will reach a value of $148 Mn from $73 Mn in 2022, growing at a CAGR of 9.3% during 2022-30. The Oncology Therapeutics Market in Tanzania is dominated by a few domestic pharmaceutical companies such as MCL Pharmaceuticals, Labatec Pharma, and Pristine Pharma. The Oncology Therapeutics Market in Tanzania is segmented into different types of cancer and different therapy types. The major risk factors associated with cancer are diet, alcohol, tobacco, air pollution, and physical inactivity. The demand for Tanzania Oncology Therapeutics is increasing on account of the rise in initiatives taken by the Government of the country.

ID: IN10TZPH042 CATEGORY: Pharmaceuticals GEOGRAPHY: Tanzania AUTHOR: Dr. Vishwa Modhia

Buy Now

Tanzania Oncology Therapeutics Market Analysis Summary

By 2030, it is anticipated that the Tanzania Oncology Therapeutics Market will reach a value of $148 Mn from $73 Mn in 2022, growing at a CAGR of 9.3% during 2022-30.

Tanzania is a low-income, developing country in East Africa bordering the Indian Ocean. Cancer is Tanzania's biggest noncommunicable disease, followed by diabetes and cardiovascular disease. Cancer cases in Tanzania have been steadily increasing. According to the International Agency for Research on Cancer (IARC), 42,060 new cases of cancer are recognised each year in Tanzania, with a high mortality rate of 28,610 deaths per year, indicating that many patients are diagnosed at advanced stages. Patients in Tanzania have access to cancer care's four pillars: prevention and education, early detection and diagnosis, treatment, and palliative care.

Cervical cancer, prostate cancer, and breast cancer are the most frequent cancers in Tanzania. Tanzania's government spent 3.8% of its GDP on healthcare in 2020.

Tanzania Oncology Therapeutics Market Analysis

Market Dynamics

Market Growth Drivers Analysis

Daily smoking is practised by 19.8 % of men and 2.2 % of women in Tanzania. Tanzania reported 96 % of its people using solid fuels in 2017, which causes a rise in cancer incidence. Major cancer centres include the Aga Khan Hospital Dar es Salaam, Bugando Medical Centre, Kilimanjaro Christian Medical Centre, and the Ocean Road Cancer Institute. Tanzania's government is working hard to address the country's rising cancer burden. Tanzania will receive its first PET scan machine and a newer intensity-modulated radiation treatment (IMRT) system this year. Tanzania is putting together a regional cooperation strategy. Furthermore, the country receives international aid in the form of concessional loans. These aspects could boost Tanzania Oncology Therapeutics Market.

Market restraints

A cancer diagnosis is disturbing anywhere in the world, but it is typically a death sentence in Tanzania. Because 80 % of cases are found at an advanced stage, supportive care and symptom management are frequently all that is available. Tanzania has a scarcity of cancer treatment facilities. Furthermore, not all patients are able to travel long distances to receive treatment. Many people would prefer not to be treated. The path to treatment, the financial burden, the availability of cancer facilities, the availability of chemotherapy and radiation therapy, a lack of knowledge, and the stigma associated with cancer all contribute to people not seeking medical attention in Tanzania. These factors may deter new entrants into the Tanzania Oncology Therapeutics Market.

Competitive Landscape

Key Players

MCL Pharmaceuticals Ltd: This is a Tanzanian pharmaceutical company that produces a range of oncology drugs, including chemotherapy agents, supportive care medications, and targeted therapies
Labatec Pharma Ltd: This is another Tanzanian pharmaceutical company that produces oncology drugs such as chemotherapy agents, hormonal agents, and targeted therapies
Tropikal Brands Afrika Ltd: This is a Tanzanian healthcare company that produces a range of oncology drugs, including chemotherapy agents, supportive care medications, and targeted therapies
Galaxy Pharmaceutical Ltd: This is a Tanzanian pharmaceutical company that specializes in the production of oncology drugs, including chemotherapy agents, hormonal agents, and targeted therapies
Pristine Pharma Ltd: This is a Tanzanian pharmaceutical company that produces a range of oncology drugs, including chemotherapy agents, supportive care medications, and targeted therapies
TanPharMed Ltd: This is a Tanzanian pharmaceutical company that produces a range of oncology drugs, including chemotherapy agents, hormonal agents, and targeted therapies

Healthcare Policies and Reimbursement Scenarios

In Tanzania, the administrative body liable for supporting and observing oncology therapeutics is the Tanzania Food and Drug Authority (TFDA). As an example, Tanzania has a public health care coverage plan known as the National Health Insurance Fund (NHIF). The public authority has carried out different drives to resolve this issue, including the Tanzania Oncology Drugs Access Program (TODAP), which expects to work on the accessibility and reasonableness of disease drugs in the country. Most Tanzanians lack insurance and are impoverished. While not all cancer centres provide free care, there is still a long waiting list for cancer treatment, especially considering the scarcity of institutions equipped with the necessary diagnostic and therapeutic technology.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Oncology Therapeutics Segmentation

By Application (Revenue, USD Billion):

Blood Cancer
?Colorectal Cancer
Gastrointestinal Cancer
Gynaecologic Cancer
Breast Cancer
Lung Cancer
Prostate Cancer
?Others

By Drugs (Revenue, USD Billion):

Revlimid
Avastin
Herceptin
Rituxan
Opdivo
Gleevec
Velcade
Imbruvica
Ibrance
Zytiga
Alimta
Xtandi
Tarceva
Perjeta
Temodar
Others

By Therapy (Revenue, USD Billion):

Chemotherapy
Targeted Therapy
Immunotherapy
Hormonal Therapy
Others

By Route of Administration (Revenue, USD Billion):

Oral
Parenteral
Others

By Distribution Channel (Revenue, USD Billion):

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
?Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.

To request a free sample copy of this report, please complete the form below.

We value your inquiry and offer free customization with every report to fulfil your exact research needs.

Yes, I have read the privacy policy

By 2030, it is anticipated that the Tanzania Oncology Therapeutics market will reach a value of $148 Mn from $73 Mn in 2022, growing at a CAGR of 9.3% during 2022-2030.

In Tanzania, the regulatory body responsible for approving and monitoring oncology therapeutics is the Tanzania Food and Drug Authority (TFDA).

The Oncology Therapeutics Market in Tanzania is dominated by a few domestic pharmaceutical companies such as MCL Pharmaceuticals, Labatec Pharma, and Pristine Pharma.